LakeShore Biopharma Receives Revised Offer
Ticker: LSBWF · Form: 6-K · Filed: Aug 28, 2025 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Aug 28, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, offer, corporate-action
TL;DR
LakeShore Biopharma got a new offer, details TBD.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K report on August 28, 2025. The filing includes a press release announcing the receipt of a revised preliminary non-binding offer. The company is located in Beijing, PRC.
Why It Matters
This filing indicates ongoing strategic discussions or potential transactions that could significantly impact the company's future structure or ownership.
Risk Assessment
Risk Level: medium — The filing concerns a revised preliminary offer, suggesting potential changes in corporate structure or ownership, which inherently carries uncertainty.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- YS Biopharma Co., Ltd. (company) — Former company name
- YishengBio Co., Ltd (company) — Former company name
- August 2025 (date) — Reporting period
- 001-41598 (other) — Commission file number
FAQ
What is the nature of the revised preliminary non-binding offer?
The filing mentions the receipt of a revised preliminary non-binding offer in Exhibit 99.1, but the specific details of the offer are not provided in the summary text.
When was LakeShore Biopharma Co., Ltd. previously known by other names?
The company was formerly known as YS Biopharma Co., Ltd. since March 10, 2023, and prior to that as YishengBio Co., Ltd. since September 12, 2022.
What is the primary business address of LakeShore Biopharma?
The principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
What type of report is this filing?
This is a Form 6-K report, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Does LakeShore Biopharma file annual reports under Form 20-F or 40-F?
The filing indicates that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 183 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2025-08-28 08:34:09
Filing Documents
- ea0254943-6k_lakeshore.htm (6-K) — 10KB
- ea025494301ex99-1_lakeshore.htm (EX-99.1) — 24KB
- 0001213900-25-081400.txt ( ) — 35KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release - LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: August 28, 2025 2